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Herein we provide a concise review of the state of methylation research as it pertains to clinical oral cancerous and precancerous
tissues. We provide context for ongoing research eﬀorts in this ﬁeld and describe technologies that are presently being applied to
analyze clinical specimens. We also discuss the various recurrent methylation changes that have been reported for oral malignancy
(including those genes frequently silenced by promoter methylation and the small RNAs with activity modulated by methylation
changes) and describesurrogatedisease markers identiﬁed viaepigenetic analysis ofsaliva and bloodspecimens frompatients with
oral cancer.
1.Background
Oral cancer remains a major global killer [1]. Its entrenched
poor survival rates make essential the ongoing molecular
evaluation of oral cancers and precancers for the purpose of
uncovering new tools for detecting and treating this disease.
As with most solid epithelial tumors, oral cancers develop
through a series of histopathological stages; hyperplasia
leads to various degrees of dysplasia, which are followed by
carcinoma in situ and ﬁnally invasive disease stages. The
accumulation of various genetic and epigenetic alterations
is understood to drive this progression paradigm. Herein
we will discuss the role of DNA methylation in clinical oral
tumorigenesis, focusing speciﬁcally on oral squamous cell
carcinomas (OSCCs).
DNA methylation occurs most frequently at cytosine
residues of CpG dinucleotides in gene promoter regions, and
much less frequently, within a gene [2]. CpG islands (CpG-
rich regions spanning >500bp with >55% GC content)
exist in approximately 60–70% of promoters in the human
genome [2, 3]. Methylation in the promoter region of a given
gene can serve to decrease expression of that gene. This is
thought to occur by either physically inhibiting the binding
of proteins essential for transcription, or by recruiting pro-
teins that have transcription repressive properties [4]. This
reversible process helps govern gene expression activity in
individual cells and is commonly disrupted in cancer, where
gene silencing via methylation in particular can contribute
toKnudsoniantwo-hitdisruptionoftumorsuppressorgenes
[5].
Further, global hypomethylation of genes is understood
to serve as a mechanism of oncogene activation, providing
another avenue for methylation changes to contribute to
tumorigenesis. In addition to being identiﬁed as an early
event in tumorigenesis for many epithelial cancers, aber-
rant methylation has also been identiﬁed in dysplasia—
andtumor—adjacent“normal”tissues,indicatingadditional
complexity at this level of epigenetic dysregulation.
2. TechniquesandMethodologiesforEvaluating
Methylation Changes
Myriad technologies exist for detecting DNA methylation
alterations and most of these have already been applied
in an oral cancer context. The most common technique2 Journal of Oncology
is methylation-speciﬁc PCR (MSP). This approach involves
bisulfate conversion of unmethylated cytosines within CpG
islands of the genome, with methylated cytosines unchanged
by this conversion. In MSP, following design of primers for
both methylated and unmethylated sequences of a speciﬁc
locus, converted DNA is ampliﬁed and then separated by
gel electrophoresis. Diﬀerential analysis of resultant MSP
products—say for tumor versus patient-matched normal
tissues—reveals changes in methylation status. MSP is par-
ticularly useful because it has suﬃcient sensitivity to detect
one methylated cytosine in 1000 and the primers used are
also highly speciﬁc (i.e., have a low false positive rate). MSP
is also a relatively quick and aﬀordable technique, though its
limitations include the reality that it is more qualitative than
quantitative and the fact that it is generally unhelpful for the
assessment of genome-wide methylation changes.
Other techniques for evaluating methylation changes are
built on the principles underpinning MSP. MethyLight—
which integrates sodium bisulﬁte conversion and quanti-
tative ﬂuorescence PCR—oﬀers a sensitive, highly speciﬁc,
and rapid means for assessing methylation status for a
particular locus [6]. This technique involves use of primers
with a ﬂuorescent 5 reporter dye (typically FAM) and a 3
quencher dye. During ampliﬁcation, Taq DNA polymerase
cleaves the probe and releases the reporter dye. The resultant
ﬂuorescence is quantiﬁed by laser in associated equipment
and will be proportional to the number of methylated
cytosines at a given locus. This approach allows a more
precise quantitation of methylation status compared to MSP,
which can only be measured qualitatively. Additionally,
MethyLight has been shown to be more sensitive than MSP
by a factor of ten (detecting even one methylated cytosine in
10,000) [6].
Sequence alterations resulting from bisulﬁte conversion
can remove cut sites recognized by speciﬁc restriction
enzymes. For example, if methylation has been lost, the cut
siteforBstUImaybelostviaconversionofaCGCGsequence
to TGTG. COBRA (combined bisulﬁte restriction analysis)
leverages this fact to allow quantiﬁcation of methylation
in PCR products generated following bisulﬁte conversion
[7]. Ultimately, the amount of total methylation per locus
corresponds to the degree to which the strands are cut by
the restriction enzyme. The strength of this technique lies in
its quantitative results, ease of use, and compatibility with
paraﬃn embedded samples. However, COBRA does have
its limitations, as it is a locus speciﬁc technique and thus
unhelpful for a genome wide analysis.
Pyrosequencing is a technique that is quantitative, easy
to use, and accurate [8]. It utilizes a sequence-by-synthesis
method that monitors the bioluminometric signal that
results when a pyrophosphate group is released during DNA
synthesis. This technique can assess the methylation status
of genes by bisulphate conversion, PCR, and subsequent
comparison of the ratio of T and Cs in the samples.
A recurring disadvantage to the above techniques is
the fact that they do not easily facilitate global analyses
of methylation changes; they are all locus-speciﬁc. Several
techniquesforglobalevaluationofchangesinthemethylome
have been developed to address this issue. Currently, the
most common approach for genome-wide analysis involves
methylation-speciﬁc microarrays. A range of arrays are avail-
able, but most are based on one of three general principles to
sample processing: (MSRE) methylation-sensitive restriction
enzyme digests, methylation-speciﬁc immunoprecipitation,
or sodium bisulﬁte conversion [9].
Regarding enzyme digestion approaches, sample pro-
cessing with endonucleases speciﬁc to methylation sites
(e.g., HpA1I) was one of the ﬁrst methods of array-based
methylation proﬁling [10]. There are several diﬀerent types
of arrays that use this approach. For example, in diﬀeren-
tial methylation hybridization arrays, DNA is digested by
MSREs. This pool of DNA fragments is labeled with one
ﬂuorescent dye, and a pool of the same sample with no
digestion is labeled with second dye. They are concurrently
hybridized on an array and relative signal intensities are
measured to determine methylation status at a given locus
[10]. This method of methylation proﬁling can interrogate
everything from hundreds of diﬀerent CpG islands to the
entire genome. These approaches all have relatively high
sensitivity; however, their utility for analyzing disease tissues
can be variable as DNA sample input requirements can
be quite high, requiring approximately 2μgo ft i s s u e ,a n d
clinical lesions—particularly premalignant ones—can be
quite small (thus limiting the amount of specimen available
for analysis). Additionally, these methylation arrays can be
pronetofalsepositives,havealowthroughputasonlyseveral
samples can be processed in parallel, and analysis is limited
to those sequences that possess recognition sites for the
restriction enzyme associated with a given platform [9].
Immunoprecipitation of either methylated DNA or
chromatin, known as MeDIP and ChIP, respectively, has
also been used to facilitate global analyses of methylation
alterations [11, 12]. These methods use antibodies to pull
down material of interest and subsequently subject it to
microarray analysis. This method has the ability to detect
methylation status at a genome-wide level, does not require
speciﬁc primers, and avoids the sequence bias introduced
by restriction enzyme methods [9]. However, this technique
can also have lower throughput than other approaches and
has low sensitivity to methylated areas that occur in CpG
poor regions. Additionally, instead of microarray analysis of
pulled down material, ChIP-Seq combines immunoprecipi-
tation with sequencing technology to elucidate protein-DNA
interactions on a genome-wide scale [13].
A third common approach to methylation-speciﬁc mi-
croarrays involves use of the sodium bisulﬁte conversion
methods described above. Illumina arrays oﬀer one platform
based on this approach [14]. These arrays are automated in
use and allow analysis of hundreds of samples simultane-
ously. They are also capable of delineating methylation status
for thousands of CpG sites (if not the entire genome), allow
determinationofthemethylationstatusofspeciﬁcCpGsites,
and have relatively low sample input requirements (thus
more readily facilitating analysis of low yield clinical tissues).
That said, this technique can introduce bias via incomplete
bisulﬁte conversion reactions and PCR.
Lastly, a technique that is rapidly becoming increasingly
common is whole genome bisulﬁte sequencing. Due toJournal of Oncology 3
improvements in protocols, increase of throughput, and
the rapid decline of sequencing cost, this method is robust
and highly sensitive. In brief, this protocol involves bisulﬁte
conversion, PCR ampliﬁcation, and sequencing of products
to determine methylation status to a single base pair
resolution [15]. Historically, this method was problematic
due to processing errors of bisulﬁte conversion, degradation
of DNA due to long processing times, and the need
for a relatively large amount of sample [16]. However,
improvements on protocols have greatly increased eﬃciency
of this technique, which has great promise for the proﬁling
of methylation status.
3. Genes Evincing Methylation Changes in Oral
SquamousCellCarcinomas
As speciﬁc genes are implicated as critical drivers of malig-
nant phenotypes, they become attractive candidates for
e v a l u a t i o na st a r g e t so fn o v e lt h e r a p e u t i c so ra sb i o m a r k -
ers for guiding patient management decisions. Recurrent
methylation-mediated alterations of several genes have been
reported for all invasive epithelial cancer types, includ-
ing oral tumors. It is understood that in general cancer
cells exhibit increased global hypomethylation with speciﬁc
regions of hypermethylation. However, it is currently not
known how speciﬁc genes are targeted. The major etio-
logical factors for oral squamous cell carcinoma (OSCC)
are smoking, alcohol use, and (to a lesser extent) Human
Papillomavirus (HPV) infection [17]. How these factors
inﬂuence DNA methylation in oral tumorigenesis has not
been evaluated. However, smoking has been shown in other
cancer types to activate DNA methyltransferase 1 (DNMT1)
which catalyzes DNA methylation [18, 19]. A summary of
speciﬁc genes implicated in oral cancers and understood to
be governed by methylation changes follows below.
CDKN2A, mapping to chromosome 9p21.3, produces
two major proteins: p16(INK4), which is a cyclin-dependent
kinase inhibitor, and p14(ARF), which binds the p53-
stabilizing protein MDM2 and is involved in cell cycle
control. Deletion at this locus is regularly reported to be one
of the earliest events in oral cancer initiation and progression
[20]. Hypermethylation of the CDKN2A promoter region
has been extensively evaluated in oral cancers with the
frequency of hypermethylation being reported as anywhere
from 28% to 86% [21, 22]. Aberrant methylation of this
locusinnoncancercontrolshasnotbeendetected[23–25].A
panel of cell lines was investigated for homozygous deletion,
hypermethylation, and point mutations at p16, with results
indicating that the ﬁrst two alteration types were the more
common modes of p16 disruption in OSCC [26].
In a speciﬁc cohort of betel chewing individuals with oral
cancer, methylation of p16 was detected in 63% of OSCCs
and 67% of verrucous carcinomas [27]. In a panel of indi-
viduals of Indian descent, methylation of p16 was detected
in 23% of OSCC cases [24]. In general, data do suggest
that diﬀerences in patient ethnicity, etiological factors, and
tissue type (since the OSCC category actually spans diﬀerent
tissues) can inﬂuence the molecular alterations detected for
disease.
Several groups have correlated methylation of
p16INK4A/p14ARF with various clinical features for
oral cancers, though results have varied. In one study, it was
observed that people with p16 promoter methylation had
a lower mean age, a higher risk of lymph node invasion in
young patients, a higher risk of distant metastasis in older
patients, and shortened disease free survival in older patients
[28]. Other work showed that p16INK4A methylation was
associated with increased likelihood of disease recurrence,
whereas p14ARF is associated with lower recurrence rates
[29]. Concurrent promoter hypermethylation of p16 and
p14 correlated signiﬁcantly with tumor size and lymph node
metastasis and with later stage of OSCC in one study [30],
while a separate study found methylation of p14ARF alone
correlated with a good prognosis for patients [31]. Larger
scale trials are needed to ﬁne tune how methylation status
of p16 and p14 promoters may best be applied to manage
clinical decisions.
P16 promoter methylation has been assessed for squa-
mous cell carcinomas of the tongue as well as in margin
tissues that remain in patients following surgical resec-
tions. As expected, tumors showed a high frequency of
p16 promoter hypermethylation (86.8%) [32]. Regarding
tissues at surgical margins—which were all histologically-
characterized as disease-free—43.3% exhibited p16 pro-
moter hypermethylation [32]. Signiﬁcantly, those cases with
margin tissues harboring p16 hypermethylation had a 6.3-
fold increased risk for local recurrence.
Similarly, a separate group assessed p16 promoter hyper-
methylation status in OSCC tumors, associated normal
tissues, and a panel of healthy controls [33]. They found no
methylation of p16 in the healthy control group whereas p16
methylationinOSCC-associatednormaltissueswasdetected
for 27.3% of cases (and in all of those cases, concurrent p16
hypermethylation was also detected for matched tumors).
In this study, clinical features and habitual factors did not
correlate with methylation status. Another study did not
report prognostic signiﬁcance for p16 methylation, again
showing that there is lingering ambiguity regarding whether
p16 hypermethylationwillhaveutilityasaclinicalbiomarker
[34].
E-cadherin (CDH1) plays a critical role in cell adhesion
processes and is known to signiﬁcantly inﬂuence epithelial
tissue architecture [35]. With respect to malignancy, it
is known to function as a suppressor of invasion and
metastasis formation and has previously been reported as
undergoing hypermethylation-mediated silencing in several
cancer types [35]. Previous studies of tongue squamous cell
carcinomarevealedthatdownregulationofCDH1expression
via promoter hypermethylation was signiﬁcantly associated
with poorer rates of disease-free survival [36]. Independent
reports have conﬁrmed association of epigenetically-silenced
CDH1 expression and poorer overall survival for oral cancer
(also demonstrating that CDH1 promoter hypermethylation
is associated speciﬁcally with poorer survival for node-
positive cases and individuals with stage III disease) [34].4 Journal of Oncology
Other groups, on the other hand, while reporting associa-
tions between CDH1 promoter hypermethylation and oral
cancers (when compared to normal oral mucosa), have
failed to detect signiﬁcant associations between these same
clinical parameters and this epigenetic event [28]. Indepen-
dent evaluation based on a large OSCC patient cohort is
needed to more accurately determine the signiﬁcance of
the methylation status of CDH1 vis-` a-vis clinical outcomes
(something that can also be said for other genes reported as
epigenetically dysregulated in oral tumors).
O6-methylguanine-DNA methyltransferase (MGMT)i sa
DNA repair gene that protects from toxicity and mutations
that occur by alkylating agents through the removal of O6-
guanine DNA adducts. CpG island hypermethylation of the
MGMT promoter region results in gene silencing, with loss
of MGMT repair capacity thought to drive cancer progres-
sion via the emergence of genomic instability. Decreased
expression of MGMT via epigenetic silencing has been
reported for many cancer types and loss of its expression can
be tied to greater sensitivity to alkylating chemotherapeutic
agents [37]. Epigenetic silencing of MGMT has been asso-
ciated with OSCCs where tobacco exposure and betel quid
chewing are suspected etiological factors [38–40]. MGMT
promoter hypermethylation has also been associated with
poorer outcomes for oral cancer, including a greater likeli-
hood of nodal metastases, tumor recurrence, and decreased
survival [41, 42]. MGMT promoter hypermethylation has
also been associated with poorer outcomes for oral cancer,
including a greater likelihood of nodal metastases, tumor
recurrence,anddecreasedsurvival[32,33].ReducedMGMT
expression has also been associated with these parameters
in head and neck squamous cell carcinomas generally, and
OSCCs speciﬁcally [41, 43]. Ongoing or elevated MGMT
expression has been associated with resistance to alkylating
agents in multiple cancer types including gliomas, astro-
cytomas, and melanomas [44, 45]. While alkylating agents
such as ifosfamide and cyclophosphamide have been applied
to manage various stages of oral and other head and neck
malignancy, we have not found any reports to date regarding
the role of MGMT silencing in modulating response to these
compoundsinthesecancertypes[46,47].Existingdatafrom
other cancer types provide a strong rationale for pursuing
such studies.
Death-associated protein kinase (DAPK) encodes a ser-
ine/threonine kinase that is required for apoptosis induced
by IFN-γ [48]. Loss of its expression via promoter hyperme-
thylation has been associated with formation of metastases
and advanced disease stages in multiple cancer types, includ-
ing head and neck cancers [38, 48, 49]. Regarding OSCCs,
DAPK hypermethylation has been reported as associated
with increased likelihood of lymph node involvement,
though these results have not always attained statistical
signiﬁcance [34, 50]. Interestingly, other groups have not
reported associations between these clinical features and
hypermethylation of DAPK (or other genes discussed here)
[42, 51]. Again, this may be a function of the tissue hetero-
geneity that exists within the oral squamous cell carcinoma
category. Detection of DAPK promoter hypermethylation
at resection margins of oral tumors has been signiﬁcantly
associated with decreased overall survival, suggesting that it
may have utility as a biomarker for guiding patient follow-
up strategies [52]. As with MGMT, DAPK hypermethylation
has also been associated with oral tumors where tobacco
consumption is a suspected etiological factor [39].
The TGFβ superfamily transcription factor, runt-related
transcription factor 3 (RUNX3), functions as a tumor
suppressor gene and is involved in mediating apoptotic
processes[53].Promoterhypermethylation-mediatedsilenc-
ing of RUNX3 has been reported for many cancer types
[53]. Recently, hypermethylation of the RUNX3 promoter
region was found to be signiﬁcantly associated with the
presence of lymph node metastases and tumor stage in
tongue carcinomas [52]. Other groups have reported that
reduced RUNX3 expression or promoter hypermethylation
is associated not only with progression in oral cancers, but
also with disease recurrence and poorer prognoses [52]. The
fact that other groups have not found signiﬁcant associations
between RUNX3 promoter hypermethylation and patient
outcomes suggests that the role of epigenetic silencing of
this gene in oral cancers bears further scrutiny [54]. The
emerging role of RUNX3-mediated perturbation of the
canonical Wnt signaling pathway in oral cancers also needs
to be further evaluated.
3.1. Wnt Pathway Genes. Dysregulation of the canonical
Wnt signaling pathway—via disrupted function of genes
such as adenomatous polyposis coli (APC),A X I N 1 ,β-catenin
(CTNNB1), and secreted frizzled-related proteins (SFRPs)—
has been noted for a variety of cancer types, including
oral malignancies [55–58]. Brieﬂy, canonical Wnt signaling
involvesstabilizingCTNNB1.WhenthecanonicalWntpath-
way is inactive, CTNNB1 exists in a phosphorylated form
and is marked for degradation, with this phosphorylation
mediated by a protein complex that incorporates Glycogen
Synthase Kinase 3β (GSK3β), APC, and AXIN proteins.
WhenWntbindstoreceptorsencodedbyFrizzled(Fz)genes,
Dishevelled (Dsh) is activated and, consequently, GSK3β is
inhibited. This in turn causes CTNNB1 dephosphorylation,
which stabilizes the molecule and allows it to accumulate
in the cell nucleus, where it can induce TCF/LEF-mediated
transcription of several target genes. Regarding oncogenic
processes, the downstream eﬀects of CTNNB1 activation
via Wnt signaling include enhanced cell proliferation and
antiapoptotic activity.
Given their role as Wnt antagonists, SFRPs function as
tumor suppressors. Marsit et al., reporting on head and
neck cancers in general, described methylation diﬀerences
for SFRP genes based on alcohol consumption, smoking
behaviors,andHPV16status[59].Morespeciﬁcally,multiple
reports involving analysis of both oral cancer cell lines
and clinical OSCC cases have reported that promoter
hypermethylation for SFRPs is associated with disease [60,
61]. Interestingly, the ﬁndings in these studies for SFRP1
have been conﬂicting, with both hypermethylation and
demethylation of this gene reported [60–62].
APC also functions as a tumor suppressor gene and
has also been reported as downregulated in oral tumors.Journal of Oncology 5
Disruption of APC function in OSCC has been attributed
to loss of heterozygosity (LOH alterations), mutations, and
epigenetic alterations [63]. Regarding the latter, in vitro
studies demonstrated that treatment with demethylating
agent 5-aza-2-deoxycytidine resulted in restoration of APC
expression in oral cancer cells, supporting the functional
importance of epigenetic silencing for this gene [64]. The
drug received FDA approval for the treatment of myelodys-
plastic syndrome and is currently in clinical trials testing its
utility in the treatment of several solid tumors. Increased
promoter methylation for APC has been reported in clinical
oral cancer tissues and some data do suggest a relationship
between APC methylation status and development of lymph
node metastases when it is analyzed in concert with the
promoter methylation status of CDH1 [34].
As described above, activation of CTNNB1 is a critical
consequence of canonical Wnt pathway signaling—and
a variety of oncogenic processes can be turned on by
this activity [56]. Elevated expression and greater nuclear
localization of CTNNB1 have been reported for oral cancer
and a multitude of other cancer types [56, 65]. While
recent work has shown CTNNB1 immunostaining levels to
be signiﬁcantly associated with lymph node status, survival
outcomes, and diﬀerent invasive stages for oral cancers, data
regarding the association of CTNNB1 methylation status for
this disease have not [66]. Data from other cancer types
suggest that activating mutations of CTNNB1 that prevent
its downregulation may be a more common event than
methylation [67].
WIF1 functions as a tumor suppressor that inhibits
Wnt signaling through direct interaction with Wnt proteins,
its activation leading to cell cycle arrest [56]. It has been
described as downregulated in several cancer types [56].
Promoter hypermethylation-mediated downregulation of
WIF1 in oral cancers has been reported by multiple groups,
so there is evidence to suggest that epigenetic alteration
of this gene can contribute to invasive disease phenotypes
[52, 61]. More recently, a group studying tongue cancers
found no signiﬁcant associations between WIF1 promoter
hypermethylation and lymph node metastasis formation,
tumor stage, or overall survival [52]. In a separate study,
this same group found no signiﬁcant association between
WIF1 promoter hypermethylation status in tissues from
histologically negative resection margins and oral cancer
recurrence [52]. Results so far suggest that WIF1 alterations
mayonlyhaveclinicalutilityasoralcancerbiomarkerswhere
used for diagnosis of invasive disease.
Figure 1 places the genes discussed in this section in their
proper context in the canonical Wnt signaling cascade.
4. Methylation Changes Governing Behavior of
Noncoding RNAs in Oral Cancers
Noncoding RNAs, particularly microRNAs (miRNAs), have
been shown to play a role in many biological processes and
cellular pathways—and their behavior has been shown to be
modulatedbymethylationchanges[68,69].MiRNAsare19–
24 nucleotide transcripts that regulate mRNA expression by
binding to and subsequently silencing the mRNA target [70–
72]. MiRNAs can act as oncogenes or tumor suppressors and
have been identiﬁed as dysregulated in several cancer types,
including oral cancer [73–77]. As is the case with protein
coding genes, there are several mechanisms that can lead
toabnormalmiRNAexpression,includinghypermethylation
of CpG island promoters [78–82]. Using a functional-based
screen in two OSCC cell lines, Uesugi et al. proﬁled tumor
suppressive miRNAs that are silenced by hypermethylation
[76]. They identiﬁed 110 miRNAs that exhibited inhibitory
properties and, when compared to additional cell lines and
tumor tissue, they found that miR-218 and miR-585 were
frequently silenced by DNA hypermethylation [76].
Separate work has also shown that silencing of four
tumor suppressive miRNAs (miR-34b, miR-137, miR-193a,
and miR-203) can be mediated by aberrant methylation in
OSCC cells [68]. This same work reported downregulation
of miRNA expression through tumor-speciﬁc hypermethy-
lation as being more frequent for miR-137 and miR-193a
than for miR-34b and miR-203 when analyzed in primary
tumors and paired normal oral mucosa. A separate group
investigated the association between promoter methylation
of miR-137 and both overall survival and disease-free
survival, as well as with various prognostic factors [83].
This study found an association between methylation at the
miR-137 promoter and poorer overall survival, though no
associations were observed with disease-free survival or any
of the other evaluated prognostic factors. MiR-137 has been
reported as a negative regulator of CDK6/CCND1-mediated
cell cycle progression [84], hence promoter methylation
might serve as a means of inactivating tumor suppressive
miR-137 function. Langevin et al. suggest that their inability
to detect associations between miR-137 and other prognostic
features in their study may have been a product of factors
such as limited sample sizes and insuﬃc i e n t l yl o n gf o l l o w u p ,
proposing that stronger associations between miR-137 and
oral cancer outcomes may exist [83]. Very recent work has
suggested that epigenetically-mediated miR-137 expression
may diﬀer in oral cancer cells depending on whether they
are part of a stem-like subpopulation [85]. The argument for
further evaluation of miR-137 in the context of oral cancer
outcomes is bolstered by evidence from other cancer types
that also suggest a tumor suppressive biological role for this
miRNA and an association with poorer disease outcomes
[86–88]. Though only a few reports have evaluated the
impact of methylation changes on small RNA behaviors in
oral cancers and precancers, these early data do suggest a role
for these molecules in oral malignant processes and provide
a strong rationale for further studies in this area.
5. AlteredMethylationStates
inOral PremalignantLesionsand
Cancer Progression
Premalignant lesions in the oral cavity are readily detectable
owing to the accessibility of the organ site. That said, one
factor that contributes to the poor prognosis of OSCC
is the current inability to determine which premalignant6 Journal of Oncology
CKIε
Porc Cer-1
Dsh
Metastasis, 
angiogenesis, and 
cancer progression
Wnt9 
LRP5/6
CK2
FRAT1 PAR-1
Nkd
CKIα
Sox17
ICAT
CHD8
Axam
NLK
CBP
Idax
PS-1
CtBP
Groucho
TAK1
PP2A
PPARδ c-myc
cycD
CTNNB1 CTNNB1
Fz
GSK3β GSK3β
Dsh Dsh
WIF1 WIF1
Dsh
TCF/LEF TCF/LEF
APC APC
Wnt Wnt
SFRP SFRP
Dkk
AXIN1 AXIN1
Proliferation
Differentiation
Dally Vangl1 Knypek Fz Fz
Figure1:AnoverviewofthecanonicalWNTsignalingpathway.GeneshighlightedinthispaperasimplicatedinOSCCareshadedgrey.Gene
interactions are shown as activating (arrows) or inhibiting (blocked arrows). Boxes indicate processes that will ultimately be inﬂuenced by
WNT signaling. Solid lines represent direct interactions and dashed lines indicate indirect eﬀects. Lines connecting genes represent binding
or association interactions. Complexes are represented by ovals that overlap.Journal of Oncology 7
lesionswillultimatelyprogresstoinvasivedisease;theclinical
standard of care is “watchful waiting” since histopathological
review is presently incapable of delineating progression
risk and intervention with all early lesions would lead to
overtreatment that is costly both in terms of dollars and
patient quality of life. Since earlier stage lesions are smaller
insize andmorereadilytreatable,biomarkersdelineating the
progression likelihood for a given dysplasia case represent a
key means for improving patient outcomes.
Several studies have indicated that deletion and silencing
of loci mapping to chromosome arms 9p and 3p are
common events in the early development of OSCC [89, 90].
Thus, studies investigating the role methylation changes
in oral premalignant lesion (OPL) behavior have generally
investigated genes mapping within these regions.
More speciﬁcally, several studies have investigated the
impact of methylation changes p14 and p16—both of which,
as described above, are encoded by CDKN2A and map to
chromosome9p21.3—inOPLs.Amuchhigherdegreeofp16
promoterhypermethylationhasbeenreportedrelativetop14
promoter hypermethylation in patients with histologically
conﬁrmed severe dysplasias (57.5% and 3.8% resp.) [91].
Another group reported that p16 hypermethylation in OPLs
was associated with a greater risk for progression to invasive
disease; patients with conﬁrmed OPLs (as determined by
WHO criteria and independent review by two pathologists)
that harbored hypermethylated p16 promoters were approx-
imately two and a half times more likely to develop OSCC
than patients with OPLs that did not exhibit p16 promoter
hypermethylation [92]. Interestingly, another study reported
higher rates of promoter methylation for neighboring p15
relative to p16 across multiple stages of histopathologically
conﬁrmed oral dysplasia (50% versus 18%) [93]. This
same study also reported a much higher frequency of p14
promoter methylation; though the fact that analyzed tissues
came from a population of betel quid chewers—where the
suspected disease etiology was therefore diﬀerent than other
populations (where tobacco is the predominant etiological
factor)—may have impacted these results.
Another study assessed whether hypermethylated genes
previously implicated in oral dysplasias could be used as
markers for progression likelihood [94]. In this instance,
longitudinal follow-up data made this evaluation possible
since progression status for each patient with clinically
conﬁrmed disease was known. Interestingly, the results of
this work suggested a much lower incidence of promoter
methylation at previously identiﬁed candidate genes than
in the studies discussed above. The authors in this instance
posited that use of pyrosequencing instead of MSP may
explain the discrepancy, the former technique being less
prone to false positives. This study did conclude that p16
could be a predictor of progression, though its speciﬁcity
came in at a fairly low value (57%).
Though wealth of clinical data associated with canonical
genomic alterations at chromosome 9p and 3p makes these
regions attractive for locus-speciﬁc analysis of methylation
alterations, other loci are also worthy of further scrutiny
for the utility in predicting disease progression. 14-3-3-σ
has also found to be recurrently methylated in histologically
conﬁrmed oral dysplasias and has been associated with
coincident methylation at p16, making it an attractive can-
didate for further evaluation in an oral cancer progression
context [95].AnothergroupobservedthatRECK,agenethat
functions to inhibit angiogenesis, invasion, and metastasis,
has a potential to be a biomarker as it is recurrently found
to be hypermethylated in the normal mucosa adjacent to
the tumor [96]. Ultimately, whole methylome analyses of a
large panel of well-annotated OPLs with extensive followup
are needed to uncover disease-relevant biomarkers that will
impact disease management and oral cancer survival rates.
6. Global Methylome Changes and the Role
of HypomethylationinOral Malignancy
In addition to investigating the methylation status of speciﬁc
genes, some studies have begun analyzing the oral cancer
methylome as a whole. Early evidence suggests that the
distribution of methylation at various gene promoters across
a series of lesions of progressing grade from a single
individual can follow a speciﬁc pattern. Further, the CpG
island methylation phenotype (CIMP) has been observed in
several cancer types and is based on the observation that
those tumors exhibiting aberrant methylation of one gene
are more likely to have other sites of aberrant methylation
[97, 98]. To determine whether the CIMP phenomenon was
detectable in OSCC, the methylation status of ten genes
was evaluated in a large panel of oral tumors [99]. This
analysis revealed a cluster of tumors with a greater degree
of promoter methylation than would be predicted by chance
alone. These cases were identiﬁed as “CIMP +ve” and results
suggest (1) that these tumors exhibited a less aggressive
tumor biology than other oral cancers and (2) that these
cases were characterized by a greater host inﬂammatory
response (a ﬁnding which the authors note is consistent with
ﬁndings in other cancer types). Another group has reported
observing CIMP in head and neck cancers, though it is clear
additional studies are needed to elucidate the mechanisms
driving this phenotype [100].
While the majority of literature has focused on pro-
moter hypermethylation silencing of tumor suppressor
genes as a critical mechanism driving oral tumorigenesis,
DNA hypomethylation is also understood to contribute
to development of many epithelial cancers by facilitating
activation of candidate oncogenes [101]. More speciﬁcally, it
has been proposed that DNA hypomethylation contributes
to tumorigenesis by two potential mechanisms. The ﬁrst
represents another global level of methylation dysregulation,
where highly methylated repetitive elements (such as long
interspersed nuclear element-1 LINE-1 and Alu sequences)
are demethylated, resulting in increased chromosomal insta-
bility that leads to irregular mitoses that, in turn, drive the
emergence of further mutations that can activate oncogenes
[97, 102, 103]. The second is more speciﬁc, where inadver-
tentdemethylationinalocalcontextactivatesoncogenesthat
are normally methylation-silenced in the human genome
[97, 102, 103].8 Journal of Oncology
With respect to oral cancer speciﬁcally, little work has
been done in clinical tissues. Analysis of in vitro OSCC
models of interleukin-mediated chronic inﬂammation have
indicated that chronic inﬂammation can drive both global
hypomethylation of LINE-1 sequences as well as speciﬁc
CpG methylation changes [104]. More precisely, this model
showed that IL-6 speciﬁcally was inducing these changes,
with methylation alterations also found to be associated with
downstream changes in gene expression. The suggestion that
inﬂammatory responses can play a critical role in mediating
cancer-causing methylation changes is of particular interest
giventhattheoralcavity,whichexperiencesregularexposure
to carcinogens, is frequently under inﬂammatory stress.
Another group investigated the role of hypomethylation in
a murine model of oral cancer which used DNMT1 hypo-
morphicallelestoreducegenomicmethylationaslingualand
esophageal carcinogenesis was induced by 4-nitroquinoline
1-oxide [105]. This group reported that reduction of DNA
methylation levels led to the suppression of tumor formation
in certain cell types.
A separate group detected global LINE-1 hypomethyla-
tion in oral rinses obtained from OSCC patients (relative
to healthy controls) [106]. This is touched on further
in the following section. The relative scarcity of studies
addressing either global trends in the oral cancer methylome
or the role of speciﬁc instances of hypomethylation in oral
tumorigenesis points to a need to develop these research
s t r e a m sm o r ef u l l y .
7.MethylationChangesasSurrogateMarkers
for Oral Malignancy
7.1. Saliva. The use of saliva for the diagnosis or establishing
prognosis of OSCC patients is a promising screen, as it is
both noninvasive and inexpensive. The potential of this tool
has been studied by utilizing a genome-wide methylation
array to proﬁle the methylation status of 13 OSCC patients
before and after surgery, as well as ten normal samples
[107]. This work identiﬁed 34 genes of interest, including
p16, and proposed panels ranging from 4–7 genes that are
likely to have the optimal sensitivity and speciﬁcity for
clinical applications (the range of speciﬁcity being 62–77%
and sensitivity being 83–100%). This group also used saliva
samples taken from the same patients at both the pre- and
postoperative stages, eliminating issues arising from using
saliva samples from unmatched normal subjects as a control.
Another group analyzed the methylation status of 11
genes by MSP for a panel of primary tumors and saliva sam-
plesfrom90patientswithHNSCC[108].Theyfoundseveral
genesthatwerefrequentlymethylatedinthepairedsalivaand
tissue samples including previously-implicated candidates
such as p16, MGMT, DAPK,a n dRASSF1. Additionally, they
were able to accurately detect malignant cells in saliva several
months before tumor recurrence was otherwise detected in
patients, indicating that saliva-based assays may be a very
useful tool for eﬀective followup of oral cancer patients.
As referenced above, a separate study of oral rinses
identiﬁed LINE-1 hypomethylation as being more prevalent
in rinses obtained from OSCC patients when compared to
healthy controls [106]. While the authors did not establish
any statistically signiﬁcant associations between their rinse
results and disease stage, histological grade, lesions site,
or carcinogen exposures (e.g., tobacco smoke), the utility
of this noninvasive approach for diﬀerential diagnosis of
oral malignancy does suggest it is worth evaluating in
independent patient cohorts.
To assess the potential of saliva as a screen for pre-
malignant lesions, another group collected saliva samples
from patients that had leukoplakia and were at risk for the
development of OSCC [109]. They assessed the methylation
status of p16, p14, and MGMT from these specimens using
MSP and observed a relatively high frequency of hyperme-
thylation of MGMT and p16 relative to levels typically found
in OSCC patients. However, followup had not been done on
the patients, so whether or not the hypermethylation of p16
and MGMT was unique to patients at risk for progressing
into OSCC is not known.
7.2. Serum. In addition to saliva rinses, methylation changes
detected in DNA isolated from serum from peripheral blood
also hold potential as a diagnostic or prognostic tools for
detection and management of disease. This approach has
previously been used in a variety of other cancers such
as lung, liver, and colorectal [110–112]. As with studies
involving saliva, the methylation status of p16 has been the
predominant focus of this work in oral cancer.
One group found that parallel evaluation of pro-
moter methylation status of multiple genes (including p16)
improved the sensitivity and speciﬁcity of disease discrimi-
nation[113].Anothergroupsimilarlyanalyzedthepromoter
methylation status of multiple genes in serum samples
obtained from OSCC cases and found that in a majority of
cases, at least one of the four assayed genes was detectable
as hypermethylated [49]. It has been reported that when a
gene is found to be hypermethylated within a tumor, DNA
from a matched peripheral blood sample will harbor similar
methylation changes at a frequency ranging from 31 and
54.5% [49, 114, 115].
Evaluation of methylation alterations in samples ob-
tained by minimally invasive procedures such as collection
of saliva or blood remains a very attractive avenue for the
discovery of biomarkers for management of clinical oral
malignancy. Expanded collection eﬀorts and evaluation of
these biological materials should be a component of all
molecular investigations of oral cancers and precancers.
8. Conclusion
Interrogation of methylation changes in clinical oral cancers
and precancers has revealed multiple recurrent alterations
at genes and chromosomal loci that are associated with
oncogenic processes in this and other cancer types. Some
analyses have indicated strong associations between these
changes and speciﬁc patient outcomes, including the likeli-
hood of progressing from premalignant to invasive disease
andposttreatmentrecurrence.EvaluationofbloodandsalivaJournal of Oncology 9
samples, that are easily accessible, has also generated data
that methylation changes detected in these specimens might
have utility as surrogate biomarkers for managing disease.
Giventhat oralcancersandprecancersrepresent asigniﬁcant
global health challenge, these more aﬀordably processed
specimen types should be of particular research interest
going forward if the ﬁeld is serious about developing tools
with utility worldwide. We conclude that changes in DNA
methylation from clinical tissues do show early promise as
markers to improve management for this cancer type, which
has had survival rates that have remained stubbornly low
over recent decades. We ultimately feel that the true utility
of methylation markers for management of oral malignancy
will only be realized when analyses are expanded to much
larger patient cohorts. This reasoning holds whether the
methylation status is being evaluated for an individual locus
or by the most current and robust platform for whole
methylome analysis. We also feel that a much stronger
research emphasis on developing new methylation markers
for managing smaller, more treatable premalignant lesions
would address a currently underserved path for improving
oral cancer outcomes.
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